Daniel C Aguirre-Acevedo1, Francisco Lopera2, Eliana Henao2, Victoria Tirado2, Claudia Muñoz2, Margarita Giraldo2, Shrikant I Bangdiwala3, Eric M Reiman4, Pierre N Tariot4, Jessica B Langbaum4, Yakeel T Quiroz5, Fabian Jaimes6. 1. Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia2Academic Group of Clinical Epidemiology, University of Antioquia, Medellín, Colombia. 2. Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia. 3. Department of Biostatistics, University of North Carolina at Chapel Hill. 4. Banner Alzheimer's Institute, Phoenix, Arizona. 5. Neuroscience Group of Antioquia, University of Antioquia, Medellín, Colombia5Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston. 6. Academic Group of Clinical Epidemiology, University of Antioquia, Medellín, Colombia6Research Unit, Hospital Pablo Tobón Uribe, Medellín, Colombia.
Abstract
IMPORTANCE: Data from an autosomal dominant Alzheimer disease (ADAD) kindred were used to track the longitudinal trajectory of cognitive decline associated with preclinical ADAD and explore factors that may modify the rate of cognitive decline. OBJECTIVES: To evaluate the onset and rate of cognitive decline during preclinical ADAD and the effect of socioeconomic, vascular, and genetic factors on the cognitive decline. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective cohort study from January 1, 1995, through June 31, 2012, of individuals from Antioquia, Colombia, who tested positive for the ADAD-associated PSEN1 E280A mutation. Data analysis was performed from August 20, 2014, through November 30, 2015. A mixed-effects model was used to estimate annual rates of change in cognitive test scores and to mark the onset of cognitive decline. MAIN OUTCOMES AND MEASURES: Memory, language, praxis, and total scores from the Consortium to Establish a Registry for Alzheimer Disease test battery. Chronologic age was used as a time scale in the models. We explore the effects of sex; educational level; socioeconomic status; residence area; occupation type; marital status; history of hypertension, diabetes mellitus, and dyslipidemia; tobacco and alcohol use; and APOE ε4 on the rates of cognitive decline. RESULTS: A total of 493 carriers met the inclusion criteria and were analyzed. A total of 256 carriers had 2 or more assessments. At the time of the initial assessment, participants had a mean (SD) age of 33.4 (11.7) years and a mean (SD) educational level of 7.2 (4.2) years. They were predominantly female (270 [54.8%]), married (293 [59.4%]), and of low socioeconomic status (322 [65.3%]). Word list recall scores provided the earliest indicator of preclinical cognitive decline at 32 years of age, 12 and 17 years before the kindred's respective median ages at mild cognitive impairment and dementia onset. After the change point, carriers had a statistically significant cognitive decline with a loss of 0.24 (95% CI, -0.26 to -0.22) points per year for the word list recall test and 2.13 (95% CI, -2.29 to -1.96) points per year for total scores. Carriers with high educational levels had an increase of approximately 36% in the rate of cognitive decline after the change point when compared with those with low educational levels (-2.89 vs -2.13 points per year, respectively). Onset of cognitive decline was delayed by 3 years in individuals with higher educational levels compared with those with lower educational levels. Those with higher educational level, middle/high socioeconomic status, history of diabetes and hypertension, and tobacco and alcohol use had a steeper cognitive decline after onset. CONCLUSIONS AND RELEVANCE: Preclinical cognitive decline was evident in PSEN1 E280A mutation carriers 12 years before the onset of clinical impairment. Educational level may be a protective factor against the onset of cognitive impairment.
IMPORTANCE: Data from an autosomal dominant Alzheimer disease (ADAD) kindred were used to track the longitudinal trajectory of cognitive decline associated with preclinical ADAD and explore factors that may modify the rate of cognitive decline. OBJECTIVES: To evaluate the onset and rate of cognitive decline during preclinical ADAD and the effect of socioeconomic, vascular, and genetic factors on the cognitive decline. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective cohort study from January 1, 1995, through June 31, 2012, of individuals from Antioquia, Colombia, who tested positive for the ADAD-associated PSEN1E280A mutation. Data analysis was performed from August 20, 2014, through November 30, 2015. A mixed-effects model was used to estimate annual rates of change in cognitive test scores and to mark the onset of cognitive decline. MAIN OUTCOMES AND MEASURES: Memory, language, praxis, and total scores from the Consortium to Establish a Registry for Alzheimer Disease test battery. Chronologic age was used as a time scale in the models. We explore the effects of sex; educational level; socioeconomic status; residence area; occupation type; marital status; history of hypertension, diabetes mellitus, and dyslipidemia; tobacco and alcohol use; and APOE ε4 on the rates of cognitive decline. RESULTS: A total of 493 carriers met the inclusion criteria and were analyzed. A total of 256 carriers had 2 or more assessments. At the time of the initial assessment, participants had a mean (SD) age of 33.4 (11.7) years and a mean (SD) educational level of 7.2 (4.2) years. They were predominantly female (270 [54.8%]), married (293 [59.4%]), and of low socioeconomic status (322 [65.3%]). Word list recall scores provided the earliest indicator of preclinical cognitive decline at 32 years of age, 12 and 17 years before the kindred's respective median ages at mild cognitive impairment and dementia onset. After the change point, carriers had a statistically significant cognitive decline with a loss of 0.24 (95% CI, -0.26 to -0.22) points per year for the word list recall test and 2.13 (95% CI, -2.29 to -1.96) points per year for total scores. Carriers with high educational levels had an increase of approximately 36% in the rate of cognitive decline after the change point when compared with those with low educational levels (-2.89 vs -2.13 points per year, respectively). Onset of cognitive decline was delayed by 3 years in individuals with higher educational levels compared with those with lower educational levels. Those with higher educational level, middle/high socioeconomic status, history of diabetes and hypertension, and tobacco and alcohol use had a steeper cognitive decline after onset. CONCLUSIONS AND RELEVANCE: Preclinical cognitive decline was evident in PSEN1E280A mutation carriers 12 years before the onset of clinical impairment. Educational level may be a protective factor against the onset of cognitive impairment.
Authors: Lei Yu; Patricia Boyle; Robert S Wilson; Eisuke Segawa; Sue Leurgans; Philip L De Jager; David A Bennett Journal: Neuroepidemiology Date: 2012-07-17 Impact factor: 3.282
Authors: Natalia Acosta-Baena; Diego Sepulveda-Falla; Carlos Mario Lopera-Gómez; Mario César Jaramillo-Elorza; Sonia Moreno; Daniel Camilo Aguirre-Acevedo; Amanda Saldarriaga; Francisco Lopera Journal: Lancet Neurol Date: 2011-02-04 Impact factor: 44.182
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: F Panza; C Capurso; A D'Introno; A M Colacicco; V Frisardi; A Santamato; M Ranieri; P Fiore; G Vendemiale; D Seripa; A Pilotto; A Capurso; V Solfrizzi Journal: J Nutr Health Aging Date: 2008 Jun-Jul Impact factor: 4.075
Authors: Yakeel T Quiroz; Chantal E Stern; Eric M Reiman; Michael Brickhouse; Adriana Ruiz; Reisa A Sperling; Francisco Lopera; Bradford C Dickerson Journal: J Neurol Neurosurg Psychiatry Date: 2012-11-07 Impact factor: 10.154
Authors: Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Napatkamon Ayutyanont; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Hua Mo; Liliana Lopez; Sonia Moreno; Natalia Acosta-Baena; Margarita Giraldo; Gloria Garcia; Rebecca A Reiman; Matthew J Huentelman; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera; Eric M Reiman Journal: Lancet Neurol Date: 2012-11-06 Impact factor: 44.182
Authors: D C Aguirre-Acevedo; R D Gómez; S Moreno; E Henao-Arboleda; M Motta; C Muñoz; A Arana; D A Pineda; F Lopera Journal: Rev Neurol Date: 2007 Dec 1-15 Impact factor: 0.870
Authors: Laura Ramirez Aguilar; Juliana Acosta-Uribe; Margarita M Giraldo; Sonia Moreno; Ana Baena; Diana Alzate; Rosario Cuastumal; David Aguillón; Lucía Madrigal; Amanda Saldarriaga; Alexander Navarro; Gloria P Garcia; Daniel C Aguirre-Acevedo; Ethan G Geier; J Nicholas Cochran; Yakeel T Quiroz; Richard M Myers; Jennifer S Yokoyama; Kenneth S Kosik; Francisco Lopera Journal: Alzheimers Dement Date: 2019-02-10 Impact factor: 21.566
Authors: Ge Li; Eric B Larson; Jane B Shofer; Paul K Crane; Laura E Gibbons; Wayne McCormick; James D Bowen; Mary Lou Thompson Journal: J Am Geriatr Soc Date: 2017-09-21 Impact factor: 5.562
Authors: Willemijn J Jansen; Rik Ossenkoppele; Betty M Tijms; Anne M Fagan; Oskar Hansson; William E Klunk; Wiesje M van der Flier; Victor L Villemagne; Giovanni B Frisoni; Adam S Fleisher; Alberto Lleó; Mark A Mintun; Anders Wallin; Sebastiaan Engelborghs; Duk L Na; Gäel Chételat; José Luis Molinuevo; Susan M Landau; Niklas Mattsson; Johannes Kornhuber; Osama Sabri; Christopher C Rowe; Lucilla Parnetti; Julius Popp; Tormod Fladby; William J Jagust; Pauline Aalten; Dong Young Lee; Rik Vandenberghe; Catarina Resende de Oliveira; Elisabeth Kapaki; Lutz Froelich; Adrian Ivanoiu; Tomasz Gabryelewicz; Marcel M Verbeek; Páscual Sanchez-Juan; Helmut Hildebrandt; Vincent Camus; Marzena Zboch; David J Brooks; Alexander Drzezga; Juha O Rinne; Andrew Newberg; Alexandre de Mendonça; Marie Sarazin; Gil D Rabinovici; Karine Madsen; Milica G Kramberger; Agneta Nordberg; Vincent Mok; Barbara Mroczko; David A Wolk; Philipp T Meyer; Magda Tsolaki; Philip Scheltens; Frans R J Verhey; Pieter Jelle Visser; Dag Aarsland; Daniel Alcolea; Myriam Alexander; Ina S Almdahl; Steven E Arnold; Inês Baldeiras; Henryk Barthel; Bart N M van Berckel; Kaj Blennow; Mark A van Buchem; Enrica Cavedo; Kewei Chen; Elena Chipi; Ann D Cohen; Stefan Förster; Juan Fortea; Kristian S Frederiksen; Yvonne Freund-Levi; Olymbia Gkatzima; Mark Forrest Gordon; Timo Grimmer; Harald Hampel; Lucrezia Hausner; Sabine Hellwig; Sanna-Kaisa Herukka; Peter Johannsen; Aleksandra Klimkowicz-Mrowiec; Sebastian Köhler; Norman Koglin; Koen van Laere; Mony de Leon; Viviana Lisetti; Wolfgang Maier; Jan Marcusson; Olga Meulenbroek; Hanne M Møllergård; John C Morris; Arto Nordlund; Gerald P Novak; George P Paraskevas; Gayan Perera; Oliver Peters; Inez H G B Ramakers; Lorena Rami; Eloy Rodríguez-Rodríguez; Catherine M Roe; Uros Rot; Eckart Rüther; Isabel Santana; Johannes Schröder; Sang W Seo; Hilkka Soininen; Luiza Spiru; Erik Stomrud; Hanne Struyfs; Charlotte E Teunissen; Stephanie J B Vos; Linda J C van Waalwijk van Doorn; Gunhild Waldemar; Åsa K Wallin; Jens Wiltfang; Henrik Zetterberg Journal: JAMA Psychiatry Date: 2018-01-01 Impact factor: 21.596
Authors: K B Casaletto; A M Staffaroni; A Wolf; B Appleby; D Brushaber; G Coppola; B Dickerson; K Domoto-Reilly; F M Elahi; J Fields; J C Fong; L Forsberg; N Ghoshal; N Graff-Radford; M Grossman; H W Heuer; G-Y Hsiung; E D Huey; D Irwin; K Kantarci; D Kaufer; D Kerwin; D Knopman; J Kornak; J H Kramer; I Litvan; I R Mackenzie; M Mendez; B Miller; R Rademakers; E M Ramos; K Rascovsky; E D Roberson; J A Syrjanen; M C Tartaglia; S Weintraub; B Boeve; A L Boxer; H Rosen; K Yaffe Journal: Alzheimers Dement Date: 2020-01 Impact factor: 21.566
Authors: J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz Journal: J Prev Alzheimers Dis Date: 2019
Authors: José L Molinuevo; Laura A Rabin; Rebecca Amariglio; Rachel Buckley; Bruno Dubois; Kathryn A Ellis; Michael Ewers; Harald Hampel; Stefan Klöppel; Lorena Rami; Barry Reisberg; Andrew J Saykin; Sietske Sikkes; Colette M Smart; Beth E Snitz; Reisa Sperling; Wiesje M van der Flier; Michael Wagner; Frank Jessen Journal: Alzheimers Dement Date: 2016-11-05 Impact factor: 21.566